Literature DB >> 2450535

The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tripeptide in IGF-1 for binding.

L Szabo1, D G Mottershead, F J Ballard, J C Wallace.   

Abstract

The insulin-like growth factor binding protein (BP) secreted by bovine kidney (MDBK) cells has been purified by affinity chromatography on a rat IGF-2 Sepharose column. Purified BP migrated as a single band of Mr 40,000 upon SDS polyacrylamide gel electrophoresis. An N-terminal sequence of 53 residues was obtained which was very similar up to residue 21 to the corresponding rat BRL-3A BP sequence. In competitive binding experiments with bovine IGF-1 and IGF-2, and recombinant human IGF-1, BP had a similar affinity for these ligand when IGF-1 tracer was used, but a higher affinity for IGF-2 with IGF-2 as radioligand. The N-terminal destripeptide truncated form of bovine IGF-1, which has enhanced biological activity, was found to have a markedly reduced affinity for BP compared to intact IGF-1. The increased bioactivity of destripeptide IGF-1 can be explained by this reduced affinity for BP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450535     DOI: 10.1016/0006-291x(88)90580-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Glucocorticoids regulate the secretion of a 21kDa-IGF-binding protein by sheep adipose tissue explants.

Authors:  J Beattie; R G Vernon
Journal:  Mol Cell Biochem       Date:  1995-04-26       Impact factor: 3.396

2.  Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1.

Authors:  M Ross; G L Francis; L Szabo; J C Wallace; F J Ballard
Journal:  Biochem J       Date:  1989-02-15       Impact factor: 3.857

3.  Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action.

Authors:  S Mohan; C M Bautista; J Wergedal; D J Baylink
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

4.  A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide.

Authors:  C J Bagley; B L May; L Szabo; P J McNamara; M Ross; G L Francis; F J Ballard; J C Wallace
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

Review 5.  Insulin-like growth factor 1 physiology: lessons from mouse models.

Authors:  Shoshana Yakar; Martin L Adamo
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-15       Impact factor: 4.741

6.  Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.

Authors:  D Yee; R E Favoni; G S Lebovic; F Lombana; D R Powell; C P Reynolds; N Rosen
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

7.  Altered affinity of insulin-like growth factor II (IGF-II) for receptors and IGF-binding proteins, resulting from limited modifications of the IGF-II molecule.

Authors:  Y Oh; M W Beukers; H M Pham; P A Smanik; M C Smith; R G Rosenfeld
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

8.  Mutations in the B-domain of insulin-like growth factor-I influence the oxidative folding to yield products with modified biological properties.

Authors:  S J Milner; G L Francis; J C Wallace; B A Magee; F J Ballard
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

9.  Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II.

Authors:  G L Francis; S E Aplin; S J Milner; K A McNeil; F J Ballard; J C Wallace
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

Review 10.  Estrogen-IGF-1 interactions in neuroprotection: ischemic stroke as a case study.

Authors:  Farida Sohrabji
Journal:  Front Neuroendocrinol       Date:  2014-05-29       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.